Price
CHART BY
Frequently asked questions
What is BioCryst Pharms's market capitalization?
The market capitalization of BioCryst Pharms is $2.55B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for BioCryst Pharms?
BioCryst Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.504. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for BioCryst Pharms's stock?
Currently, 11 analysts cover BioCryst Pharms's stock, with a consensus target price of $20.82. Analyst ratings provide insights into the stock's expected performance.
What is BioCryst Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, BioCryst Pharms reported a revenue of $940.61M.
What is the EBITDA for BioCryst Pharms?
BioCryst Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $386.91M. EBITDA measures the company's overall financial performance.
What is the free cash flow of BioCryst Pharms?
BioCryst Pharms has a free cash flow of $356.23M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does BioCryst Pharms have, and what sector and industry does it belong to?
BioCryst Pharms employs approximately 435 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of BioCryst Pharms's shares?
The free float of BioCryst Pharms is 219.47M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.55B
- EPS (TTM)
- -$1.504
- Free Float
- 219.47M
- Revenue (TTM)
- $940.61M
- EBITDA (TTM)
- $386.91M
- Free Cashflow (TTM)
- $356.23M
Pricing
- 1D span
- $8.802$9.228
- 52W span
- $6.005$11.22
Analyst Ratings
The price target is $20.82 and the stock is covered by 11 analysts.
Buy
10
Hold
1
Sell
0
Information
BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.
- Employees
- 435
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- BCRX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet